Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Ann E. Black(PharmacoGenetics (China)), Thomas F. Woolf(University of Michigan), Michael Sinz(Rutgers, The State University of New Jersey), Roger N. Hayes(University of Michigan)
PubMed
August 1, 1998
Cited by 46
Related Papers
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol
|Clinical Pharmacokinetics|2007|174